Sponsored by Cerevel Therapeutics
Raymond Sanchez, MD
Advertisement
Chief medical officer, Cerevel Therapeutics
Articles by Raymond Sanchez, MD
The chief medical officer of Cerevel Therapeutics detailed phase 2 data of its investigational agent tavapadon, which has been studied in patients with Parkinson disease.
The chief medical officer of Cerevel Therapeutics detailed the TEMPO trials, a trio of studies that will examine tavapadon in patients with early and late-stage Parkinson disease.
Advertisement
Latest Updated Articles
Raymond Sanchez, MD: Phase 3 TEMPO Trials Guide TavapadonPublished: January 10th 2021 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Understanding Ocrelizumab’s Impact on Advanced Progressive MS: Insights From Dr. Gavin Giovannoni
2
Inside the Phase 3 MASCOT Trial: Lundbeck’s Push for the First Disease-Modifying MSA Therapy
3
FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related related Amyloid Pathology
4
Reinforce Ocrelizumab’s Role Across the Full Spectrum of More Advanced Progressive MS: Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath
5
